A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC

Inclusion Criteria:

1. Patients voluntarily entered the study and signed informed consent form (ICF);
2. Age: Be at least 18 years old and and there is no limit on the gender;
3. Clinically or histologically diagnosed as unresectable HCC;
4. There is at least one measurable lesions that meet the mRECIST standard;
5. Child-pugh classification A or B (score≤7);
6. The maximum number of TACE procedures allowed before enrolment was 2. All of thosepatients who had a history of prior TACE achieved complete response by previous TACE,but recurred more than 6 months later at the study entry
7. ECOG : 0 ~ 2 ;
8. Before the patients were enrolled in the study, doctors had decided to treat them withdonafenib in combination with TACE.

Exclusion Criteria:

1. Donafenib forbidden population:

• Those who are allergic to any component of the medicine;
• Active bleeding;
• Active peptic ulcer;
• Hypertension not controlled by drugs;
• Those with severe liver insufficiency.

2. Medical conditions that affect absorption, distribution, metabolism, or clearance ofthe study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction,absorption disorders, etc.);
3. Patients with a clear past history of neurological or psychiatric disorders;
4. The patient had been treated with another study drug or study device in the 4 weeksprior to initial dosing;
5. Pregnant or breastfeeding women, and women or men with fertility who are unwilling orunable to take effective contraceptive measures;
6. Unable to follow the research protocol for treatment or scheduled follow-up;
7. Any other researcher who thinks they cannot be included.